INTRODUCTION {#sec1-1}
============

Recent epidemiologic studies revealed that erectile dysfunction (ED), defined as the inability to attain or maintain enough erection for satisfactory sexual intercourse, has a high incidence and prevalence worldwide, affecting up to 150 million men.[@ref1][@ref2][@ref3] ED can be induced by many pathological conditions including vascular risk factors or diseases, neurologic abnormalities, and hormonal disturbances.[@ref4][@ref5] Among all such factors, hyperhomocysteinemia (HHcy), characterized by elevation of total plasma homocysteine (tHcy), attracts increasing attention as a novel risk factor for cardiovascular disorders.[@ref6] Numerous studies showed that HHcy perturbs vascular endothelial function.[@ref7][@ref8] Jones *et al.*[@ref8] reported that HHcy markedly inhibited corpus cavernosum (CC) endothelial cells (ECs) function and nitric oxide (NO) formation in animal experiments and proposed HHcy as a newly described potential risk factor for ED. Moreover, some clinical trials indicated that HHcy, known as an important contributor to endothelial dysfunction, is a determinant for ED.[@ref9][@ref10][@ref11]

Although oral phosphodiesterase (PDE) 5 inhibitors, first-line drugs for ED, are generally effective and well-tolerated therapies,[@ref12][@ref13][@ref14] they usually have limitations. PDE5 inhibitors cannot increase cyclic guanosine monophosphate (cGMP) levels if the bioavailability of endogenous NO is restricted, as their effects rely on endogenous formed NO. This also explains why these drugs fail to relieve ED in men with severe cardiovascular disease. Therefore, novel treatment methods are urgently needed for patients responding poorly to PDE5 inhibitors.

Tissue kallikrein-1 (KLK1) is a glycoprotein of the serine proteinase superfamily, initially discovered as a hypotensive agent in human urine.[@ref15][@ref16] It processes low-molecular-weight kininogen (LMWK) to produce vasoactive kinins, which exert such biological functions as decreasing cardiac and renal injuries, restenosis, and ischemic stroke, and promoting angiogenesis and skin wound healing, all via kinin receptor signaling.[@ref17] Previous studies in transgenic animals harboring the human tissue *KLK1* (*hKLK1*) gene showed that *KLK1* induced a variety of beneficial biological effects, including increasing endothelial function,[@ref18] anti-apoptosis, anti-fibrosis, and decreasing oxidative stress.[@ref19][@ref20][@ref21] We showed that hKLK1 play a preventive role in age-related ED in our previous study,[@ref22] and have been studying whether hKLK1 could be used to preserve erectile function in the presence of HHcy.[@ref23][@ref24]

We established a rat model of HHcy in male Sprague--Dawley (SD) rats, induced by a methionine (Met)-rich diet. We then examined the effect of HHcy on erectile function and CC in this model. Moreover, whether harboring the *hKLK1* gene could preserve erectile function in the rats with HHcy was also studied. Our results provided an experimental basis for the use of *hKLK1* as an alternative therapy for ED.

MATERIALS AND METHODS {#sec1-2}
=====================

 {#sec2-1}

### Acquisition of the transgenic rats {#sec3-1}

As shown in our previous study,[@ref22] we obtained transgenic rats harboring the *hKLK1* gene (TGRs) as a generous gift from the Max Delbrück Center for Molecular Medicine (Berlin, Germany). The TGRs were generated by microinjecting a 5.6-kb DNA fragment containing the entire *hKLK1* gene, under the control of heavy metal-responsive mouse metallothionein promoter, into the oocytes of SD rats. The presence of the transgene in genomic DNA was verified by Southern blot. Offspring with the homozygous *hKLK1* gene were selected for further experiments.

### Animals and treatment {#sec3-2}

This study was approved by the Academic Administration Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China. All animal experiments were performed based on the guideline of the Animal Ethical Committee for Animal Experiments in China. A total of 40 male SD rats were used, including 30 wild-type rats (WTRs), obtained from the Laboratory Animal Center of Tongji Medical College (HUST), and 10 TGRs. The 30 WTRs, 10 weeks of age and weighing 300--350 g, were randomly divided into three groups (*n* = 10 per group): control, low-dose (4% Met), and high-dose (7% Met). The Met enriched diets were fed orally to the rats of 4% Met and 7% Met groups daily for 1 month. The 10 age-matched TGRs, designated as the TGR+7% Met group, were also fed 7% Met diet for a month. All rats were individually housed in a conventional animal facility with laminar flow, maintained at 20°C ± 1°C and 50% ± 10% relative humidity with a 12 h light/12 h dark photoperiod, and bred by professional breeders.

### Verification of TGR {#sec3-3}

Measurements at the levels of genome, genomics transcription and translation were used to detect the presence and expression of the *hKLK1* gene in the CC of rats. The presence of *hKLK1* gene in the genomic DNA obtained from frozen CC samples was detected through conventional polymerase chain reaction (PCR) and agarose gel electrophoresis. The primer sequences are listed in **[Supplementary Table 1](#T1){ref-type="table"}**. mRNA and protein expressions were assayed by real-time reverse transcriptase-PCR (RT-PCR) and western blot analysis, respectively.

###### 

Primers used in conventional polymerase chain reaction and real-time reverse transcriptase-polymerase chain reaction

  -------------------------------------------------------------------------
  *Genes*    *Primer sequences*                 *Usage (PCR)*
  ---------- ---------------------------------- ---------------------------
  *hKLK1*    F: 5'GTCCAGAAGGTGACAGACTTCAT3'     Conventional

             R: 5'GTCCTCGATCCACTTCACATAAG3'\    Realtime
             F: 5'CTCACAGCTGCTCATTGCATC3'\      
             R: 5'GCTCTCACTGACATGAACAAACTGG3'   

  *rKLK1*    F: 5'CCCACACACAGATGGTGACAGA3'      Realtime

             R: 5'CCTTGAAGCACACCATCACAGAG3'     

  *βactin*   F: 5'AAGAGCTATGAGCTGCCTGAI3'       Conventional and realtime

             R: 5'TACGGATGTCAACGTCACAC3'        
  -------------------------------------------------------------------------

RT-PCR: reverse transcriptase-polymerase chain reaction; *hKLK1*: human tissue kallikrein-1; *rKLK1*: rat tissue kallikrein-1

### Measurement of erectile function {#sec3-4}

As reported in our previous studies,[@ref22][@ref25] the rat carotid artery was cannulated (PE-50 tubing; Kindly, Shanghai, China) for continuous measurement of arterial pressure to get the mean arterial pressure (MAP). Then, cavernous nerve was isolated on the posterolateral aspect of the prostate gland, followed by the electrical stimulation with a bipolar electrode at 15 Hz frequency, with a 1.2-ms width for 1 min. A 25G needle (Kindly) was inserted into the right crura to continuously monitor intracavernosal pressure (ICP). All data were recorded by a data acquisition system (PowerLab 4SP; ADInstruments, Dunedin, New Zealand). Erectile response was elicited by electrical field stimulation with 2.5 V and 5 V. The ratios of maximum (max) ICP and the area under the ICP curve (AUC) to MAP were calculated to evaluate penile erectile function.

After the measurement, the middle region of the skin-denuded penile shaft was maintained overnight in 4% paraformaldehyde (Beyotime Biotechnology, Haimen, China) and then embedded in paraffin for histologic studies. The remaining two penile tissues were harvested and stored at −80°C for real-time RT-PCR, western blot, and enzyme-linked immunosorbent assay (ELISA). In addition, these rats' blood samples were obtained from the carotid artery for subsequent experiments.

### Determination of antioxidant activity {#sec3-5}

CC tissues were stored at −80°C until they were assayed for antioxidant activity. Test kits for measuring malondialdehyde (MDA, S0131, Beyotime Biotechnology) and superoxide dismutase (SOD, S0101, Beyotime Biotechnology) were used according to the manufacturer\'s protocol. Penile MDA levels and SOD activities were normalized to the wet weight of penile tissue samples.

### Masson\'s trichrome staining {#sec3-6}

CC tissue samples from rats were sectioned transversely (5-μm thickness). Smooth muscle and collagen content were quantitatively analyzed in Masson\'s trichrome-stained sections, examined at ×100 magnification. The ratios of areas of smooth muscle (red) to areas of collagen (blue) were considered to reflect the tissue fibrosis. These data were calculated using ImagePro Plus software (Media Cybernetics, Silver Spring, MD, USA) in five randomly selected sections per group.

### Assessment of apoptosis {#sec3-7}

Terminal deoxynucleotidyl transferase 2'-deoxyuridine 5'-triphosphate nick end labeling (TUNEL) staining was used to assess apoptosis in the CC. Penile sections were processed in accordance with the instructions of the *In situ* Cell Death Detection Kit (Roche Diagnostic Corporation, Indianapolis, IN, USA). Nuclei were stained with hematoxylin (Beyotime Biotechnology). Five sections per group were randomly selected and assessed at ×400. The apoptosis level was expressed at the ratio of apoptotic to total cells in the CC sections.

### Immunohistochemistry {#sec3-8}

Sections (5-μm thickness) were incubated overnight at 4°C with antibodies against α-smooth muscle actin (α-SMA; 1:100; Abcam, Cambridge, MA, USA). Sections were then washed three times and incubated with a biotinylated secondary antibody (1:1000; Proteintech, Wuhan, China). Finally, antigen-antibody reactions were detected by staining with diaminobenzidine (Beyotime Biotechnology). Semi-quantitative analysis was performed to evaluate staining intensities using ImagePro Plus software.

### Immunofluorescence {#sec3-9}

Sections were processed for immunofluorescence and incubated with the following primary antibodies against platelet/EC adhesion molecule (PECAM)-1 (1:100), endothelial nitric oxide synthase (eNOS; 1:50), and α-SMA (1:100; Abcam). Slides were then washed and incubated with DyLight-conjugated secondary antibodies (1:200, Abbkine, Redlands, CA, USA). Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI; Beyotime Biotechnology). Fluorescence images were acquired using an Olympus BX51 fluorescence microscope (Olympus Corporation, Tokyo, Japan).

### Real-time RT-PCR {#sec3-10}

Total RNA in the CC samples was extracted using the Multisource Total RNA Minipre Kit (Axygen, Tewsbury, MA, USA) according to the manufacturer\'s instructions. Conventional PCR and real-time RT-PCR were performed with the PrimeScript RT Master Mix and SYBR Green PCR Master Mix (TaKaRa, Dalian, China), respectively. Relative values of mRNA expression of targeted genes to that of β-actin were calculated using the 2^−ΔCT^ method. The primer sequences of *hKLK1*, rat tissue *KLK1* (*rKLK1*), and β-actin are listed in **[Supplemental Table 1](#T1){ref-type="table"}**.

### Western blot analysis {#sec3-11}

CC samples of each group were homogenized in radioimmunoprecipitation assay (RIPA) buffer (Beyotime Biotechnology) containing a protease inhibitor cocktail and phosphatase inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA). Concentrations of soluble proteins were measured using the bicinchoninic acid assay (Beyotime Biotechnology). Protein samples (40 μg per lane) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Millipore, Darmstadt, Germany). This experiment included primary antibodies against hKLK1 (1:5000; Sigma Aldrich, St. Louis, MO, USA), rKLK1 (1:1000; Sigma Aldrich), p22phox (1:500; Santa Cruz, Dallas, TX, USA), p47phox (1:1000; Sangon Biotech, Shanghai, China), gp91phox (1:500; Proteintech), vascular endothelial (VE)-cadherin (1:1000; Abcam), Occludin (1:1000; Abcam), claudin-5 (1:1000; Abcam), protein kinase B (Akt; 1:1000; Proteintech), phospho-Akt (p-Akt; Ser473, 1:1000; Cell Signaling Technology, Danvers, MA, USA), eNOS (1:500; Abcam), phospho-eNOS (p-eNOS; S1177; 1:500; Cell Signaling Technology), α-SMA (1:1000; Abcam), transforming growth factor-β1 (TGF-β1; 1:1000; Abcam), B-cell lymphoma-2 (Bcl-2, 1:1000; Affinity, Zhenjiang, China), Bcl-2 associated X protein (Bax; 1:500; Proteintech), and β-actin (1:1000; Proteintech). Membranes were then incubated with horseradish peroxidase-conjugated secondary antibodies (1:5000; Proteintech) and analyzed using an enhanced chemiluminescence detection system (Pierce, Thermo Fisher Scientific, Rockford, IL, USA).

### Statistical analyses {#sec3-12}

Results are presented as a mean ± standard deviation. Data were analyzed using one-way analysis of variance followed by Tukey\'s multiple comparison test to identify differences among multiple groups. The unpaired *t*-test was performed to analyze differences between any two groups and a value of *P* \< 0.05 was considered as statistically significant.

RESULTS {#sec1-3}
=======

 {#sec2-2}

### Metabolic parameters {#sec3-13}

There was no obvious difference in initial weight and plasma tHcy levels among the four groups. After 1 month feeding with the Met-rich diet, tHcy levels in rats in the 4% Met, 7% Met, and TGR+7% Met groups were obviously higher than that in the control group fed a standard diet (all *P* \< 0.05). Moreover, tHcy levels in the 7% Met and TGR+7% Met groups were higher than that in the 4% Met group (both *P* \< 0.05). In addition, final weights in the 4% Met, 7% Met, and TGR+7% Met groups were lower than that in the control group (all *P* \< 0.05), and were lower in the 7% Met and TGR+7% Met groups than that in the 4% Met group. Interestingly, there were no differences in tHcy levels or final weights in the 7% Met and TGR+7% Met groups (**[Supplementary Table 2](#T2){ref-type="table"}**). Together, elevated tHcy levels demonstrated that the rat model for HHcy was successfully established through Met-rich diets, consistent with previous reports.[@ref26][@ref27]

###### 

Metabolic parameters

  *Variable*                        *Control*      *4% Met*         *7% Met*         *TGR+7% Met*
  --------------------------------- -------------- ---------------- ---------------- ----------------
  Initial weight (g)                307.5±8.9      309.43±11.3      306.15±13.41     310.74±9.53
  Final weight (g)                  415.41±21.33   366.27±27.34\*   342.53±22.82\*   350.48±19.98\*
  Initial tHcy level (μmol l^−^1)   30.23±4.94     31.72±5.25       30.47±4.33       29.92±4.74
  Final tHcy level (μmol l^−^1)     31.22±5.75     84.49±15.88\*    110.77±25.28\*   105.84±17.75\*
  MAP                               97.17±11.03    98.73±10.11      100.08±9.37      98.43±8.41

Data are shown as mean±s.d.; \**P*\<0.05 when compared with the control group. Met: methionine; TGR: transgenic rat; tHcy: total plasma homocysteine; MAP: mean atrial pressure; s.d.: standard deviation

### hKLK1 inhibited erectile dysfunction induced by HHcy {#sec3-14}

Electrostimulation of the rat cavernous nerve with different voltages (2.5 V and 5 V) was performed to evaluate erectile function. Max ICP/MAP ratios in the 4% Met and 7% Met groups were sharply attenuated compared with that in the control group, and the value for the 7% Met group was also lower than for the 4% Met group (*P* \< 0.05). However, erectile function was partly improved in the TGR+7% Met group, though it was still lower than that in the control group (*P* \< 0.05). The ratios of AUC/MAP at the 2.5 V and 5 V in all four groups showed the same trends as did the max ICP/MAP values. In addition, there were no differences among the four groups in the MAP (*P* = 0.9763; **[Figure 1](#F1){ref-type="fig"}**).

![Erectile function of rats elicited by cavernous nerve electrical stimulation. Representative ICP curves through electrostimulation of (**a**) 2.5 V and (**b**) 5 V for 1 min, respectively. Ratios of both max ICP and AUC to MAP of all four groups were presented through bar graphs: (**c**) for max ICP/MAP, and (**d**) for AUC/MAP. Data are expressed as mean ± standard deviation (*n* = 10 per group). ^\*^*P* \< 0.05, ^\*\*\*^*P* \< 0.001. Met: methionine; TGR: transgenic rats; ICP: intracavernous pressure; AUC: area under the curve; MAP: mean arterial pressure.](AJA-21-508-g001){#F1}

### Verification of the hKLK1 gene expression in the CC {#sec3-15}

The presence and expression of hKLK1 gene in rat CC samples were verified at the levels of genomic DNA, mRNA, and protein. The results showed that rats in only the TGR+7% Met group contained the hKLK1 DNA fragments, and there were transcription and translation of fragments to hKLK1 mRNA and protein, respectively. In addition, rKLK1 expression was lower in the 4% Met and 7% Met groups than that in the control group at both mRNA and protein levels, and its expression in the 7% Met group was also lower than that in the 4% Met group (all *P* \< 0.05; **[Figure 2](#F2){ref-type="fig"}**). These data suggested that only the TGRs, not the WTRs, contained and expressed the hKLK1 gene in the CC.

![Verification of the existence and expression of *hKLK1* gene in CC of rats. (**a**) Representative *hKLK1* genomic DNA bands in CC through conventional polymerase chain reaction followed by agarose gel electrophoresis. Relative mRNA expression of *hKLK1* and *rKLK1* genes to β-actin in CC of all four groups by real-time reverse transcriptase polymerase chain reaction: (**b**) for *hKLK1* and (**c**) for *rKLK1*. (**d**) Representative western blot result of hKLK1 and rKLK1 proteins in CC of rats. Western blot results were presented through bar graphs with β-actin as the loading control: (**e**) for hKLK1 and (**f**) for rKLK1. Data are shown as mean ± standard deviation (*n* = 10 per group). ^\*^*P* \<0.05, ^\*\*^*P* \<0.01 and ^\*\*\*^*P* \< 0.001. Met: ethionine; TGR: transgenic rats; CC: corpus cavernosum; *hKLK1*: human tissue kallikrein-1; *rKLK1*: rat tissue kallikrein-1.](AJA-21-508-g002){#F2}

### hKLK1 inhibited oxidative stress in the CC of rats with HHcy {#sec3-16}

We determined the expression of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) subunits including p22^phox^, p47^phox^, and gp91^phox^. These subunits expression levels were higher in the 4% Met and 7% Met groups than that in the control group, and expression in the 7% Met group was higher than that in the 4% Met group. Although there were also differences between the control and TGR+7% Met groups, expression in the TGR+7% Met was much lower than that in the other groups with HHcy. MDA levels and SOD activities, both reflecting oxidative stress, were also tested using ELISA. MDA levels in the four groups showed a similar trend as did expression of NADPH oxidase subunits. SOD activities in the 4% Met and 7% Met groups were lower than that in the control group, and that in the 7% Met group was also lower than that in the 4% Met group. SOD activity in the TGR+7% Met group was slightly higher than that in the 7% Met group (all *P* \< 0.05; **[Figure 3](#F3){ref-type="fig"}**).

![hKLK1 could inhibit oxidative stress in CC of rats with HHcy. (**a**) Representative western blot results of p22^phox^, p47^phox^ and gp91^phox^ in CC of rats. Expressions of p22^phox^, p47^phox^ and gp91^phox^ with β-actin as the loading control in all four groups were presented through bar graphs: (**b**) for p22^phox^, (**c**) for p47^phox^ and (**d**) for gp91^phox^. (**e**) MDA levels determined by the ELISA method in all four groups. (**f**) SOD activities determined by the ELISA method in all four groups. Data are expressed as mean ± standard deviation (*n* = 5 per group). ^\*^*P* \< 0.05, ^\*\*^*P* \<0.01 and ^\*\*\*^*P* \< 0.001. Met: methionine; hKLK1: human tissue kallikrein-1; CC: corpus cavernosum; HHcy: hyperhomocysteinemia; TGR: transgenic rats; ELISA: enzyme linked immunosorbent assay; SOD: superoxide dismutase.](AJA-21-508-g003){#F3}

### hKLK1 preserved EC and activated Akt/eNOS pathway in CC of rats with HHcy {#sec3-17}

We determined roles of ECs and Akt/eNOS pathway in ED induced by HHcy through western blot and immunofluorescence. Expression of EC junction proteins (VE-cadherin, occludin, and claudin-5) was lower in the 4% Met and 7% Met groups than that in the control group. Their expression in the 7% Met group was also lower than that in the 4% Met group, while it was grately elevated in TGR+7% Met group compared with that in the 7% Met group. Moreover, immunofluorescence staining for PECAM-1 and eNOS in cavernous tissues showed a similar trend as did expression of EC junction proteins (all *P* \< 0.05; **Figure [4](#F4){ref-type="fig"}** and **[5](#F5){ref-type="fig"}**). In addition, western blot results of p-Akt, eNOS and p-eNOS/eNOS ratio showed similar results (all *P* \< 0.05); however, there were no differences in Akt expression among all the four groups (*P* = 0.3065; **[Figure 5](#F5){ref-type="fig"}**).

![hKLK1 could preserve EC junction protein expressions and endothelial content in CC of rats with HHcy. (**a**) Representative western blot results for VE-cadherin, occludin and claudin-5 in CC of rats of all four groups. Expressions of VE-cadherin, occludin and claudin-5 with β-actin as the loading control in all four groups were presented through bar graphs: (**b**) for VE-cadherin, (**c**) for occluding, and (**d**) for claudin-5. (**e**) Immunofluorescence results of PECAM-1 in rats of all four groups. (**f**) Ratios of PECAM-1 positive area to cavernous area were presented through bar graphs. Data are expressed as mean ± standard deviation (*n* = 5 per group). ^\*^*P* \< 0.05, ^\*\*^*P* \<0.01 and ^\*\*\*^*P* \< 0.001. Scale bars = 100 μm. Met: methionine; hKLK1: human tissue kallikrein-1; CC: corpus cavernosum; HHcy: hyperhomocysteinemia; TGR: transgenic rats; PECAM-1: platelet/endothelial cell adhesion molecule-1; EC: endothelial cell.](AJA-21-508-g004){#F4}

![hKLK1 activates Akt/eNOS signaling pathway in CC of rats with HHcy. (**a**) Immunofluorescence results of eNOS in CC of rats of all four groups. (**b**) Ratios of eNOS positive area to cavernous area were presented through bar graphs. (**c**) Representative western blot results for Akt, p-Akt, eNOS and p-eNOS in rats of all four groups. Expressions of Akt, p-Akt and eNOS with β-actin as the loading control in all four groups were presented through bar graphs: (**d**) for Akt, (**e**) for p-Akt and (**f**) for eNOS. (**g**) The ratio of p-eNOS/eNOS was presented through bar graph. Data are expressed as mean ± standard deviation (*n* = 5 per group). ^\*\*^*P* \<0.01, and ^\*\*\*^*P* \< 0.001. Scale bars = 100 μm. Met: methionine; hKLK1: human tissue kallikrein-1; CC: corpus cavernosum; HHcy: hyperhomocysteinemia; TGR: transgenic rats; Akt: protein kinase B; eNOS: endothelial nitric oxide synthase.](AJA-21-508-g005){#F5}

### hKLK1 inhibited fibrosis and apoptosis in the CC of rats with HHcy {#sec3-18}

By Masson\'s trichrome staining, the area ratios of smooth muscle cells (SMC; red) to collagen (blue) in the 4% Met and 7% Met groups were lower than that in the control group, indicating more fibrosis, and the ratio for the 7% Met group was also lower than that for the 4% Met group. The TGR+7% Met group showed less histologic changes compared with the 7% Met group, in the rats with HHcy. α-SMA expression in the four groups, as indicated by immunohistochemistry, immunofluorescence and western blot, showed the same trend as the SMC area in Masson\'s trichrome staining. Western blot also showed enhanced expression of TGF-β1 in 4% Met and 7% Met groups compared with that in the control group, and was higher in the 7% Met than in the 4% Met group. The TGR+7% Met group had lower TGF-β1 expression than the 7% Met group did (all *P* \< 0.05; **[Figure 6](#F6){ref-type="fig"}**). In addition, the apoptosis index by TUNEL staining and the Bax/Bcl-2 ratio by western blot showed the same trend in the four groups as did the TGF-β1 (all *P* \< 0.05; **Supplementary Figure 1**).

![hKLK1 could reduce fibrosis in CC of rats with HHcy. (**a**) Masson\'s trichrome staining results of CC of rats in all four groups. (**b**) Immunohistochemical staining result of α-SMA in CC of rats (×100 and ×400). (**c**) Immunofluorescence results of α-SMA in CC of rats. (**d**) Ratios of smooth muscle to collagen were presented through bar graphs. (**e**) Ratios of α-SMA positive area to cavernous area were presented through bar graphs. (**f**) Representative western blot results for α-SMA and TGF-β1 in CC of rats. Expressions of α-SMA and TGF-β1 with β-actin as the loading control in all four groups were presented through bar graphs: (**d**) for α-SMA and (**e**) for TGF-β1. Data are expressed as mean ± standard deviation (*n* = 5 per group). ^\*^*P* \< 0.05, ^\*\*^*P* \<0.01 and ^\*\*\*^*P* \< 0.001. All scale bars = 100 μm. Met: methionine; hKLK1: human tissue kallikrein-1; CC: corpus cavernosum; HHcy: hyperhomocysteinemia; TGR: transgenic rats; α-SMA: α-smooth muscle actin; TGF-β1: transforming growth factor-β1.](AJA-21-508-g006){#F6}

DISCUSSION {#sec1-4}
==========

This study is the first to describe a protective role of hKLK1 on erectile function of rats with HHcy, using the TGR model. Our data suggested that HHcy-induced ED was accompanied by oxidative stress, impaired ECs and severe fibrosis in the CC. However, enhancing the kallikrein-kinin system (KKS) through harboring the *hKLK1* gene could inhibit oxidative stress, protect the eNOS pathway, maintain the normal histologic structure of the CC, and thus, preserve erectile function in rats with HHcy.

Regarding the link between HHcy and ED, Khan *et al.*[@ref28] reported that Hcy plays a negative role in endothelium-dependent relaxation and NO formation in the rabbit CC and that this effect was potentiated by copper and reversed by SOD or catalase. Similarly, a previous study showed elevated plasma Hcy levels were strongly correlated with the occurrence of ED.[@ref9] This was consistent with our findings that high tHcy levels and impaired erectile function occurred in the rats with HHcy, and that harboring the *hKLK1* gene preserved erectile function in these animals. Moreover, we observed weight loss in the rats with HHcy, which was also reported in a previous study.[@ref26] This weight loss might be associated with a metabolic disorder induced by HHcy, supporting our findings on *rKLK1*.[@ref29] Chaussalet *et al.*[@ref30] showed increased expression of hKLK1 in human ECs exposed to Hcy. However, endothelium was not the only source of overall KLK1 expression in our experiment because the protein expressed in other cells of the CC besides ECs.

Study on ED induced by diabetes showed a close association between ED and reactive oxygen species (ROS).[@ref31] ROS are generated by NADPH oxidase, xanthine oxidase, NOS, cyclooxygenase, and lipoxygenase. NADPH oxidase, a multi-subunit enzyme, including p47^phox^, p67^phox^, gp91^phox^, p22^phox^, and p40^phox^, is considered as a major source of ROS formation in the penis. Excessive ROS in penile tissue was reported to attenuate NO bioavailability and promote apoptosis of CC SMCs, thus leading to ED.[@ref32] Similarly, we previously reported S-allyl cysteine supplementation restored erectile function in diabetic rats by preventing ROS formation through inhibition of NADPH oxidase subunit expression.[@ref33] In addition, we also found some NADPH oxidase subunits were greatly activated in the CC of rats with androgen deficiency.[@ref34] A recent study by Jiang *et al.*[@ref26] also reported oxidative stress contributed to ED induced by HHcy. Our data on NADPH oxidase subunit expression, MDA levels, and SOD activities verified the existence of oxidative stress in rats with HHcy. These effects were substantially diminished by hKLK1, demonstrating the anti-oxidation effect of hKLK1 in rats with HHcy.

Oxidative stress is considered to impair functions of normal ECs.[@ref35] ECs adhere to one another by a complex network of transmembrane adhesive proteins.[@ref36] These endothelial intercellular junctional proteins comprise tight junctions and adhere junctions. Tight junctions regulate paracellular permeability, while adhere junctions are crucial for EC growth.[@ref36][@ref37] It was reported that downregulation of the representative tight junction proteins (occludin and claudin-5) and a representative adhere junction protein (VE-cadherin) in the CC was involved in the deterioration of erectile function induced by hypercholesterolemia[@ref27] and diabetes.[@ref32] In our study, levels of endothelial intercellular junctional proteins in the four groups suggested that these junctions were impaired in the CC of rats with HHcy and that harboring the *hKLK1* gene preserved their expression. In addition to endothelial intercellular junctions, EC content is also crucial.[@ref38] PECAM-1 is a transmembrane immunoglobulin concentrated at intercellular contacts in the endothelium and is used as an EC marker. Its expression in our study indicated that a loss of ECs was involved in ED induced by HHcy, a finding consistent with previous studies in diabetic and hypercholesterolemia animals.[@ref27][@ref32] However, harboring the *hKLK1* gene preserved the EC content in the CC of rats with HHcy. Taken together, our results indicated that impaired endothelial intercellular junctional proteins and EC content were both factors involved in HHcy-induced ED, and, furthermore, that hKLK1 was protective.

NO is generated by three different isoforms of NOS: eNOS, neuronal NOS (nNOS), and inducible NOS (iNOS). Among these, eNOS is an important factor in ED.[@ref39][@ref40] In previous studies, eNOS activity was inhibited during ED induced by hypercholesterolemia,[@ref27] diabetic,[@ref32][@ref41] advanced age,[@ref22] and HHcy.[@ref26] Moreover, a low eNOS activity in the CC was also characterized by decreased eNOS phosphorylation level at the Ser1177 site under aging[@ref22] and diabetic[@ref41] conditions. We found eNOS phosphorylation and the Akt/eNOS pathway were inhibited under HHcy conditions, and that, in rats harboring the *hKLK1* gene, eNOS phosphorylation level and the Akt/eNOS pathway activity were increased.

Although ECs are believed to be associated with the ability to achieve normal penile corporal veno-occlusion, CC SMC content is another important factor. The decrease of CC SMCs content, excessive collagen deposition, and a corresponding decreased ratio of smooth muscle to collagen in the CC were all associated with age-related ED in both human and rat.[@ref42][@ref43] Moreover, fibrosis, emerged as the predominant underlying cause of ED, is also evident in various rat models, including diabetes, hyperlipidemia, and androgen deficiency.[@ref44][@ref45][@ref46] Our study found the decrease of CC SMCs, the excessive collagen deposition, and a corresponding decrease in the ratio of SMC to collagen in the CC of rats with HHcy. However, *hKLK1* gene could attenuate these pathological changes and maintain normal CC structure in rats with HHcy.

To explore why HHcy decreased the number of CC SMCs, we analyzed the apoptosis level in CC SMCs. Apoptosis is an important mechanism of cellular self-destruction and is considered to be closely associated with fibrosis. Zhang *et al.*[@ref47] reported that apoptosis was significant during fibrosis, and that decreasing apoptosis alleviated fibrosis in diabetic rats. Furthermore, Wang *et al.*[@ref48] found that androgen deficiency caused corporal fibrosis by promoting CC SMCs apoptosis in rats. We found that apoptosis levels were increased under the HHcy condition and that the *hKLK1* gene inhibited HHcy-induced apoptosis in the TGRs. This result was consistent with our previous report that hKLK1 inhibited apoptosis in the CC of aged rats.[@ref22]

Although our study elucidated several mechanisms of ED induction by HHcy, its major limitation was the absence of cell-based experiments. Moreover, the absence of total *KLK1* (human and rat) measurements was another limitation. Therefore, in future studies, we will isolate ECs and SMCs from the CC of rats and verify the effect of hKLK1 *in vitro* to further support our findings.

CONCLUSIONS {#sec1-5}
===========

This study revealed that oxidative stress, dysregulated cavernous ECs, and severe penis fibrosis were involved in ED induced by HHcy in rats, while hKLK1 preserved erectile function through inhibition of these pathophysiological changes. Thus, hKLK1 is promising as a potential preventive factor for ED induced by HHcy because of its numerous beneficial effects.
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###### 

hKLK1 could reduce apoptosis in CC of rats with HHcy. (**a**) Apoptosis levels in all four groups was determined by TUNEL method. (**b**) Apoptosis index was presented through bar graph. (**c**) Representative western blot results for Bax and Bcl-2 in CC of rats. (**d**) Ratios of Bax to Bcl-2 with β-actin as the loading control in all four groups were presented through bar graphs. Data are expressed as mean ± standard deviation (*n* = 5 for per group). \*\**P* \< 0.01, \*\*\**P* \< 0.001. &*P* \< 0.05 when compared with the control group, and \#P \< 0.05 when compared with the 7% Met group; Scale bar = 100 μm. Met: methionine; hKLK1: human tissue kallikrein-1; CC: corpus cavernosum; HHcy: hyperhomocysteinemia; TGR: transgenic rats; TUNEL: terminal deoxynucleotidyl transferase 2'-deoxyuridine 5'-triphosphate nick end labeling.
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